ImmunityBio

IBRX · Nasdaq · United States

Share price · IBRX

$6.70-1.02 (-13.21%) 3M

close as of 2026-11-18 · 24h delayed · vol 15.9M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IBRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026-17.7%
  2. 27 Oct 2026+10.5%
  3. 19 Oct 2026-8.3%
  4. 2 Oct 2026+10.8%
  5. 30 Sep 2026+6.9%
  6. 22 Sep 2026+9.9%
  7. 26 Jun 2026+11.8%
  8. 18 Feb 2026+41.9%
  9. 20 Jan 2026+17.4%
  10. 16 Jan 2026+39.7%

Share of unusual movement by asset

For each asset, the share of IBRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Nogapendekin alfa inbakicept (Anktiva) (Anktiva)
events and moves
1520%
Other company news (earnings, financing, releases naming no asset)—23%
Sessions with no dated event—57%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
IL-15 superagonistProtein / enzyme therapeutic
Non-Small Cell Lung CancerBladder CancerPancreatic Cancer
Phase 1
N/A (innate, non-antigen-specific NK-cell cytotoxicity)Cell therapy
Non-Small Cell Lung Cancer

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Nogapendekin alfa inbakicept (Anktiva)Phase 2Non-muscle Invasive Bladder Cancer (NMIBC)
Est. primary completion 2026-11 · NCT06829823 · CT.gov ↗
What to watch
2027 (4)
March 2027 (1)
Nogapendekin alfa inbakicept (Anktiva)Phase 2Long COVID, Long COVID Syndrome, Long Covid 19
Est. primary completion 2027-03 · NCT07123727 · CT.gov ↗
What to watch
May 2027 (2)
Nogapendekin alfa inbakicept (Anktiva)Phase 2Platinum-resistant Ovarian Cancer
Est. primary completion 2027-05 · NCT06710288 · CT.gov ↗
What to watch
HankPhase 2Relapsed B-Cell Non Hodgkin Lymphoma
Est. primary completion 2027-05-25 · NCT07125872 · CT.gov ↗
What to watch
December 2027 (1)
Nogapendekin alfa inbakicept (Anktiva) + HankPhase 2Relapsed B-Cell Non-Hodgkin Lymphoma
Est. primary completion 2027-12 · NCT07477366 · CT.gov ↗
What to watch
2028 (2)
May 2028 (1)
Est. primary completion 2028-05-12 · NCT07783789 · CT.gov ↗
What to watch
September 2028 (1)
Est. primary completion 2028-09 · NCT06745908 · CT.gov ↗
What to watch
2029 (2)
August 2029 (1)
Nogapendekin alfa inbakicept (Anktiva)Phase 2Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma …
Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗
What to watch
December 2029 (1)
Est. primary completion 2029-12-31 · NCT06061809 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Nogapendekin alfa inbakicept (Anktiva)Phase 2HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
Est. primary completion 2030-12-31 · NCT07628062 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

6 January 2027FDA action dateNogapendekin alfa inbakicept (Anktiva)PDUFA target date set for January 6, 2027
US, FDA · Source ↗

Recent

9 November 2026Topline resultNogapendekin alfa inbakicept (Anktiva)QUILT-2.005 meets its primary endpoint in BCG-naive NMIBC
ImmunityBio · Source ↗
14 October 2026ApprovalNogapendekin alfa inbakicept (Anktiva)FDA expands the Anktiva label to BCG-unresponsive non-muscle invasive bladder cancer
US, FDA · ImmunityBio · Source ↗
29 July 2026ApprovalNogapendekin alfa inbakicept (Anktiva)UAE grants marketing authorization for Anktiva
AE, EDE · Source ↗
19 May 2026Filing acceptedNogapendekin alfa inbakicept (Anktiva)FDA accepts sBLA for ANKTIVA plus BCG in papillary NMIBC
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$49M—$45M+ $289M short-term inv.$185M-$75M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2———+ $282M short-term inv.—-$66M operating cash flowreport ↗
2026-Q1$44M—$205M+ $176M short-term inv.$633M-$75M operating cash flowreport ↗
2025-Q3$32M—$60M+ $198M short-term inv.$67M-$69M operating cash flowreport ↗
2025-Q2$26M—$138M+ $16M short-term inv.$93M-$80M operating cash flowreport ↗
2025-Q1$17M—$61M+ $0.9M short-term inv.$130M-$86M operating cash flowreport ↗
2024-Q3$6.1M$50M$112M+ $18M short-term inv.$86M-$99M operating cash flowreport ↗
2024-Q2$1.1M$51M$130M+ $88M short-term inv.$135M-$100M operating cash flowreport ↗
2024-Q1<$0.1M$53M$133M+ $37M short-term inv.$134M-$107M operating cash flowreport ↗
2023-Q3$0.1M$48M$178M+ $12M short-term inv.$96M-$87M operating cash flowreport ↗
2023-Q2<$0.1M$53M$44M+ $2.5M short-term inv.$138M-$80M operating cash flowreport ↗
2023-Q1$0.4M$79M$88M+ $2.8M short-term inv.$116M-$84M operating cash flowreport ↗
2022-Q3$0.1M$72M$104M+ $6.9M short-term inv.$111M-$81M operating cash flowreport ↗
2022-Q2<$0.1M$63M$62M+ $21M short-term inv.$95M-$91M operating cash flowreport ↗
2022-Q1<$0.1M$55M$36M+ $156M short-term inv.$103M-$75M operating cash flowreport ↗
2021-Q3$0.1M$49M$65M+ $16M short-term inv.$88M-$73M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$113M—$88M+ $154M short-term inv.$88M-$305M operating cash flowreport ↗

ImmunityBio reported revenue of $113.29M, up 668.1% YoY, cash and equivalents of $88.33M, and a net loss of $351.4M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$15M$190M$143M+ $6.4M short-term inv.$103M-$391M operating cash flowreport ↗
2023-FY$0.6M$232M$265M+ $1.0M short-term inv.$146M-$367M operating cash flowreport ↗
2022-FY$0.2M$248M$105M+ $2.5M short-term inv.$104M-$338M operating cash flowreport ↗
2021-FY$0.9M$196M$181M+ $136M short-term inv.$87M-$274M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 16 sales ($9.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-05Simon Barry J. · directorOpen-market sale25,000$10.75$269KForm 4
2026-10-02Cohen Cheryl · directorOption exercise55,979$2.98$167KForm 4
2026-10-02Cohen Cheryl · directorOpen-market sale81,056$10.50$851KForm 4
2026-10-02Cohen Cheryl · directorOption exercise (derivative)55,979——Form 4
2026-07-02Cohen Cheryl · directorOption exercise55,979$2.98$167KForm 4
2026-07-02Cohen Cheryl · directorOpen-market sale131,210$9.50$1.2MForm 4
2026-07-02Cohen Cheryl · directorOption exercise (derivative)55,979——Form 4
2026-07-01Selecky Christobel · directorOption exercise35,064$2.98$104KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 383 reporting institutions held 177.9M shares ($1.3B, 16.7% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.26,346,443$202.1M
2STATE STREET CORP17,708,103$135.8M
3VANGUARD PORTFOLIO MANAGEMENT LLC16,322,844$125.2M
4VANGUARD CAPITAL MANAGEMENT LLC15,127,714$116.0M
5D. E. Shaw & Co., Inc.12,571,597$96.4M
6GEODE CAPITAL MANAGEMENT, LLC8,031,921$61.6M
7TWO SIGMA INVESTMENTS, LP4,385,500$33.6M
8MORGAN STANLEY4,018,869$30.8M
9Woodline Partners LP3,447,346$26.4M
10GOLDMAN SACHS GROUP INC3,237,078$24.8M
11UBS Group AG2,944,888$22.6M
12VOLORIDGE INVESTMENT MANAGEMENT, LLC2,927,552$22.5M
13NORTHERN TRUST CORP2,504,781$19.2M
14CHARLES SCHWAB INVESTMENT MANAGEMENT INC2,477,941$19.0M
15BANK OF AMERICA CORP /DE/2,447,843$18.8M